ADC Control hIgG1-Deruxtecan

Deruxtecan is an exatecan-derivative topoisomerase I inhibitor. Deruxtecan is a thiol reactive derivative of DXd that contains enzymatically cleavable peptide linker GGFG. Trastuzumab Deruxtecan, sold under the brand name Enhertu was approved by US FDA for treating metastatic HER2-postive breast cancer. This product is a control ADC for any IgG type antibody labeled with Deruxtecan, particularly any ADC made using the Antibody Deruxtecan Conjugation Kit (Cat#: CM11431). The product uses a human IgG1 subtype antibody that does not bind to the target. It has an average of 3-5 Deruxtecan loaded on each antibody and can be used for accessing the effect of Deruxtecan alone (non-specific toxicity). The product uses a very low endotoxin level antibody as a starting material (≤0.5 EU/mg by the LAL method). The preparation and purification are conducted under a pyrogen free environment.

The product is sold as 1 vial of 100 microgram (Cat# CM51103-100UG), 1 vial of 500 micrograms (Cat# CM51103-500UG), or 2 vials of 500 micrograms (Cat# CM51103-1MG). For bulk orders, please contact us for a quote.

Specification
• Physical Appearance: Colorless to white lyophilized powder in a microcentrifuge tube
• Storage Temp.: -20°C
• Purity: ≥99% of Deruxtecan labeled antibody by SEC HPLC, free of any unreacted Deruxtecan
• Endotoxin Level: ≤0.5 EU/mg by the LAL method
• Drug Over Antibody Ratio (DAR): 3 to 5 by UV ratio, HIC HPLC, and difference MALDI-TOF MS

Please contact us at for specific academic pricing.